Combination therapies based on venetoclax to treat T-ALL have garnered interest, such as venetoclax in combination with cytarabine.45,47,48 In this study, we discovered that IKZF1 inhibition by CX-4945 could reduce the transcriptional level of BCL-2, highlighting a novel strategy for overcoming drug resistance due to BCL-2 binding domain alterations and modifications. The gene discussed is BCL2; the disease is acute lymphoblastic leukemia.